Ali Tipu
Endocrinology, Diabetes & Metabolism · Oklahoma City, OKNPI 1518218304
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 417 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,665, more than ten times the $33 reported in 2020.
Across 417 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$691
- Corcept Therapeutics$675
- Novo Nordisk$673
- Xeris Pharmaceuticals, Inc.$653
- Lilly USA, LLC$512
- Bayer$433
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,024100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 43 | $691 |
| Corcept Therapeutics | 35 | $675 |
| Novo Nordisk | 38 | $673 |
| Xeris Pharmaceuticals, Inc. | 32 | $653 |
| Lilly USA, LLC | 29 | $512 |
| Bayer | 34 | $433 |
| Tandem Diabetes Care, Inc. | 17 | $398 |
| Sanofi-aventis U.S. LLC | 19 | $389 |
| Abbott | 13 | $372 |
| Amgen | 19 | $360 |
| Recordati_rare_diseases_inc. | 14 | $330 |
| Insulet Corporation | 10 | $269 |
| Boehringer Ingelheim | 14 | $265 |
| Chiesi USA, Inc. | 8 | $178 |
| Sequel Med Tech, LLC | 11 | $173 |
| AbbVie | 10 | $164 |
| Cequr Corporation | 3 | $156 |
| BETA Bionics, Inc. | 9 | $151 |
| Mannkind Corporation | 13 | $139 |
| Medtronic | 2 | $118 |
| Ascendis Pharma Endocrinology Inc | 4 | $103 |
| Radius Health, Inc. | 4 | $102 |
| IBSA Pharma Inc. | 3 | $101 |
| Novartis | 5 | $92 |
| Ascensia Diabetes Care US Inc. | 3 | $85 |
| AstraZeneca | 3 | $69 |
| Kyowa Kirin, Inc. | 3 | $69 |
| Nevro Corp. | 3 | $67 |
| Astellas Pharma US Inc | 4 | $62 |
| Antares Pharma, Inc. | 3 | $51 |
| Currax Pharmaceuticals LLC | 3 | $48 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Pfizer | 2 | $35 |
| Amarin Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$143
- RYBELSUS$112
- CeQur Simplicity$106
- MINIMED 780G$105
- Omnipod$101
How this compares
$8,057 in reported general payments places this provider in the 70th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 242 | $435,523 |
| OzempicSemaglutide | 120 | $145,586 |
| JardianceEmpagliflozin | 111 | $137,931 |
| ForteoTeriparatide | 12 | $59,874 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $53,141 |
| TrulicityDulaglutide | 37 | $46,706 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 39 | $45,053 |
| Gvoke Hypopen 2-PackGlucagon | 33 | $27,610 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $25,891 |
| FarxigaDapagliflozin Propanediol | 24 | $22,702 |
| TradjentaLinagliptin | 14 | $20,510 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $16,384 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 116 | $14,940 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $14,257 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $11,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $512 | $542,103291 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $265 | $169,473137 claims |
| Novo NordiskOzempic | $673 | $145,586120 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $389 | $45,05339 claims |
| AstraZenecaFarxiga | $69 | $22,70224 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $2,435177 claims |
| AbbVieSynthroid | $164 | $1,42614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Oklahoma City
- Christian MangrumOklahoma City$54K
- Robert ScofieldOklahoma City$15K
- Donny WynnOklahoma City$11K
- Cheryl BlackOklahoma City$8K
- Diana KennedyOklahoma City$8K
- Amanda LagrecaOklahoma City$7K
- Bassam ArodakOklahoma City$6K
- Myrto EliadesOklahoma City$5K
- Hamsa AljumailiOklahoma City$5K
- Modhi GudeOklahoma City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.